[HTML][HTML] Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
X Zhang, Y Zhang, Y Jia, T Qin, C Zhang… - Cancer Biology & …, 2020 - ncbi.nlm.nih.gov
Objective: Bevacizumab is a recombinant humanized monoclonal antibody that blocks
vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall …
vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall …
[HTML][HTML] Tumor cell response to bevacizumab single agent therapy in vitro
M Hein, S Graver - Cancer cell international, 2013 - Springer
Background Angiogenesis represents a highly multi-factorial and multi-cellular complex
(patho-) physiologic event involving endothelial cells, tumor cells in malignant conditions, as …
(patho-) physiologic event involving endothelial cells, tumor cells in malignant conditions, as …
[HTML][HTML] Effect of bevacizumab on the tight junction proteins of vascular endothelial cells
Y Jia, T Qin, X Zhang, S Liu, Z Liu, C Zhang… - American journal of …, 2019 - ncbi.nlm.nih.gov
The combination of anti-angiogenesis and chemotherapy can significantly prolong the
survival period of patients with non-squamous non-small cell lung cancer (NSCLC). But drug …
survival period of patients with non-squamous non-small cell lung cancer (NSCLC). But drug …
Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study
R Costa, A Carneiro, A Rocha, A Pirraco… - Journal of cellular …, 2009 - Wiley Online Library
Given its broad effects in endothelium, vascular endothelial growth factor (VEGF) represents
the primary rate‐limiting step of angiogenesis. Therefore, VEGF targeting therapies were …
the primary rate‐limiting step of angiogenesis. Therefore, VEGF targeting therapies were …
Challenges facing antiangiogenesis therapy: the significant role of hypoxia‐inducible factor and MET in development of resistance to anti‐vascular endothelial growth …
A Mahdi, B Darvishi, K Majidzadeh‐A… - Journal of Cellular …, 2019 - Wiley Online Library
It is now fully recognized that along with multiple physiological functions, angiogenesis is
also involved in the fundamental process and pathobiology of several disorders including …
also involved in the fundamental process and pathobiology of several disorders including …
Direct antitumor activity of bevacizumab: an overlooked mechanism?
Z Wang, J Li, J Guo, P Wei - Frontiers in Pharmacology, 2024 - frontiersin.org
Bevacizumab, a recombinant humanized monoclonal antibody targeting vascular
endothelial growth factor A (VEGFA), is pivotal in treating various malignancies (Zondor and …
endothelial growth factor A (VEGFA), is pivotal in treating various malignancies (Zondor and …
[HTML][HTML] Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
M Guyot, C Hilmi, D Ambrosetti, M Merlano, CL Nigro… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Tumor growth relies on oxygen and blood supply depending on neo-vascularization. This
process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This …
process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This …
[HTML][HTML] Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation
A Brossa, C Grange, L Mancuso, L Annaratone… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Different mechanisms of angiogenesis and vasculogenesis are involved in the development
of the tumor vasculature. Among them, cancer stem cells are known to contribute to tumor …
of the tumor vasculature. Among them, cancer stem cells are known to contribute to tumor …
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic
G Ranieri, R Patruno, E Ruggieri… - Current medicinal …, 2006 - ingentaconnect.com
Angiogenesis is important in the growth and progression of solid tumours. The main pro-
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …
[HTML][HTML] Interaction between bevacizumab and murine VEGF-A: a reassessment
L Yu, X Wu, Z Cheng, CV Lee… - … & visual science, 2008 - iovs.arvojournals.org
purpose. Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody (mAb)
approved by the United States Food and Drug Administration for cancer therapy and used …
approved by the United States Food and Drug Administration for cancer therapy and used …